A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
Conditions
Multiple Myeloma
Phase III
Volunteers
Health Professionals
What is the purpose of this trial?
The purpose of this study is to evaluate conversion rate to minimal residual disease (MRD) negativity following the addition of daratumumab to lenalidomide relative to lenalidomide alone, when administered as maintenance treatment to anti-cluster of differentiation 38 (CD38) treatment naive participants with newly diagnosed multiple myeloma who are MRD positive as determined by next generation sequencing (NGS) following high-dose therapy (HDT) and autologous stem cell transplant (ASCT), with or without consolidation therapy.
- Trial withJanssen Research & Development, LLC
- Start Date02/28/2020
- End Date10/31/2023
I'm interested in volunteering
If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343
Principal Investigator
Sub-Investigators
- Adam Boruchov, MD
- Agatha Hecht
- Andrea Brennan
- Andrea Martelli
- Armand Russo, MD
- Beverly Drucker, MD, PhD
- D. Barry Boyd, MD, MS
- David Witt, MD
- Elan Gorshein, DO, JD, MPH
- Francesca Montanari, MD
- Harold Tara Jr, MD
- James Vredenburgh, MD
- Jane Kanowitz, MD
- Jaykumar Thumar, MBBS, MD
- Jeremy Kortmansky, MD
- Johanna LaSala, MD
- Justin Persico, MD
- Karishma Mehra, MBBS
- Kathleen Fenn, MD
- Kelsey Martin, MD
- Kert Sabbath, MD, FACP
- Kristen Hoxie
- M. Sung Lee, MD
- Madeline Santiago
- Michael Cohenuram, MD
- Natalia Neparidze, MD
- Pawan Karanam, MD
- Sabrina Browning, MD
- Sara Anastasio, RN
- Sarah Carlson
- Stephanie Paine, APRN
- Stuart Seropian, MD
- Su Hsien Lim, MD
- Sudhanshu Mulay, MD
- Syed Bilgrami, MBBS
- Tara Anderson
- Terri Parker, MD
- Victor Chang, MD
- Vidya Brown
- Virginia Syombathy
- Wajih Kidwai, MD, FACP
- Last Updated11/11/2022
- Study HIC#2000025686